Actualités scientifiques destinées aux professionnels de santé

Uncontrolled Type 2 Diabetes and Degludec/Liraglutide Fixed-Ratio Combination

Uncontrolled Type 2 Diabetes and  Degludec/Liraglutide Fixed-Ratio Combination

 

 

 

Safety, Efficacy of Degludec/Liraglutide Fixed-Ratio Combination in Uncontrolled T2D

Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL VII randomized clinical trial [published online February 26, 2018]. Diabetes Care. doi: 10.2337/dc17-1114

In patients with uncontrolled type 2 diabetes receiving basal insulin and metformin, treatment with insulin degludec/liraglutide fixed-ratio combination (IDegLira) may reduce glycated hemoglobin (HbA1c) levels comparable to those of basal-bolus insulin with lower hypoglycemia rates and weight loss vs weight gain, according to a phase 3b,…

Read more: Uncontrolled Type 2 Diabetes and Degludec/Liraglutide Fixed-Ratio Combination

| Imprimer | E-mail

Allaitement et risque du diabète

Allaitement et risque du diabète

 

 

 

L'allaitement prolongé réduit l'incidence du diabète

Gunderson E.P. et al. Lactation duration and progression to diabetes in women across the childbearing years. JAMA Intern Med 2018 ; 178 : 328-337.

La durée de l'allaitement aurait un effet protecteur faible sur la survenue d'un diabète plus tard dans la vie mais ces données ne reposent que sur des études faites chez des femmes âgées qui avaient à se souvenir de la durée de l'allaitement et donc sont soumises à un certain nombre de biais.

Afin de mieux évaluer la relation entre la lactation et la progression du diabète…

Read more: Allaitement et risque du diabète

| Imprimer | E-mail

Behavior Change Technique in Type 2 Diabetes

Behavior Change Technique in Type 2 Diabetes

Behavior Change Technique in Type 2 Diabetes: An Expert Perspective

A key aspect to consider when encouraging dietary change in patients with type 2 diabetes is recognizing that food is a major source of enjoyment for most people.

Type 2 diabetes affects 30.3 million people in the United States, which represents 9.4% of the population (1). Poor diet has been strongly linked to diabetes, cardiovascular disease, and stroke (2,3). Reduced risk of diabetes and better glycemic control are associated with diets rich in legumes, whole grains, fruits, vegetables, and nuts; moderate alcohol consumption; and lower intake of refined grains, red or…

Read more: Behavior Change Technique in Type 2 Diabetes

| Imprimer | E-mail

SGLT2 Inhibitors and Cardiovascular and Renal Protective Effects in T2D

SGLT2 Inhibitors and Cardiovascular and Renal Protective Effects in T2D

SGLT2 Inhibitors Show High Cardiovascular - and Renal- Protective Effects in T2D

Zhang X-L, Zhu Q-Q, Chen Y-H, et al. Cardiovascular safety, long‐term noncardiovascular safety, and efficacy of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta‐analysis with trial sequential analysis [published online January 20, 2018]. J Am Heart Assoc. doi:10.1161/JAHA.117.007165

Results of the meta-analysis showed that SGLT2 inhibitors significantly reduced the risks of major adverse cardiac events.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed high cardiovascular- and renal-protective effects as well as good long-term noncardiovascular safety with sustained efficacy in patients with…

Read more: SGLT2 Inhibitors and Cardiovascular and Renal Protective Effects in T2D

| Imprimer | E-mail

Inhibiteurs de DPP4 et maladies inflammatoires chroniques de l’intestin

Inhibiteurs de DPP4 et maladies inflammatoires chroniques de l’intestin

Maladies inflammatoires chroniques de l'intestin : les inhibiteurs de DPP4 pourraient augmenter le risque

Devin Abrahami et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872.

L'utilisation d'inhibiteurs de DPP4 contre le diabète de type 2 pourrait accroître le risque de maladie inflammatoire chronique de l'intestin. Une étude de cohorte anglaise établit un lien entre les deux avec une augmentation du risque presque triplée entre trois et quatre ans après l'initiation du traitement. Ces travaux sont parus dans le BMJ.

L'utilisation des inhibiteurs de DPP4 utilisés contre le…

Read more: Inhibiteurs de DPP4 et maladies inflammatoires chroniques de l’intestin

| Imprimer | E-mail

Sky Poker review bettingy.com/sky-poker read at bettingy.com